Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING
JIB

Converting Blood Cells into Therapeutic Approaches for Autoimmune Disease

By BiotechDaily International staff writers
Posted on 31 Jul 2013
Cells from one individual’s blood could be transformed into autoimmune diseases therapy, disorders such as rheumatoid arthritis and Crohn’s disease.

Chang Kim, a professor of comparative pathobiology at Purdue University (West Lafayette, IN, USA), has devised an application to direct the differentiation of T-cells. The technology employs naïve T-cells, immature cells from which all T-cells develop, and stimulates them to become suppressive T-cells that block the development of painful inflammation associated with autoimmune diseases.

Naïve T-cells can be collected from a patient’s blood, treated and then re-injected, according to Prof. Kim, who also is a university faculty scholar and member of Purdue’s Center for Cancer Research and Weldon School of Biomedical Engineering. “These cells are being directed to become a type of cell that is already present in our bodies, where a fine balance between inflammatory T-cells and suppressive T-cells is maintained,” he said. “We are just tipping the scales in favor of suppressive T-cells to reduce inflammation. Because of this there are none of the toxic side effects associated with many immune-suppressive drugs. In addition, cells from one's own body aren’t rejected and remain in the body much longer. Instead of taking a pill every day, this could lead to a treatment administered, for example, every six months.”

Autoimmune diseases occur when the immune system attacks one’s own body instead of fighting off infection from bacteria, viruses, and other foreign cells. An overactive immune system sends T-cells to healthy tissue and organs where they cause inflammation and tissue destruction.

Suppressive T-cells travel to regions of inflammation and inhibit the T-cells there without substantially reducing the number of T-cells in other areas of the body where they are needed for effective immune function, according to Dr. Kim. “Treatment with suppressive T-cells has the potential to be a much more precise and targeted regulation of immune function than what currently exists,” he said. “Treating autoimmune diseases without compromising a patient’s immune system has been a big problem in the field. We need to catch the thief without taking down the house, and this has that potential.”

Prof. Kim discovered that naïve T-cells cultured in the presence of the hormone progesterone can be induced to become suppressive T-cells. This project’s articles were published July 2013 in the Journal of Immunology and the European Journal of Immunology. The group also filed a patent based on this work.

Laboratory mice research showed that about 500,000 suppressive T-cells are needed to have an effect on inflammation, according to Prof. Kim. “More work needs to be done to determine the appropriate dosage of cells for a human patient, but the amount of blood many people regularly donate would likely yield multiple treatments,” he said.

In the next phase, Prof. Kim plans to explore at the molecular level how progesterone causes the cells to differentiate into suppressive T-cells and to discover the proteins and protein receptors involved. He stressed that a better determination of the molecular regulation of these cells could lead to a way to control their differentiation and function without using progesterone.

Related Links:

Purdue University




comments powered by Disqus

Channels

Drug Discovery

view channel
Image: Synthetic ion transporters can induce apoptosis by facilitating chloride anion transport into cells (Photo courtesy of the University of Texas, Austin).

Experimental Drug Kills Cancer Cells by Interfering with Their Ion Transport Mechanism

An experimental anticancer drug induces cells to enter a molecular pathway leading to apoptosis by skewing their ion transport systems to greatly favor the influx of chloride anions. To promote development... Read more

Therapeutics

view channel
Image: Liver cells regenerated in mice treated with a new drug (right) compared with a control group (center) after partial liver removal. Healthy liver cells are shown at left (Photo courtesy of Marshall et al, 2014, the Journal of Experimental Medicine).

New Drug Triggers Liver Regeneration After Surgery

Investigators have revealed that an innovative complement inhibitor decreases complement-mediated liver cell death, and actually stimulates postsurgery liver regrowth in mice. Liver cancer often results... Read more

Business

view channel

Partnership Established to Decode Bowel Disease

23andMe (Mountain View, CA,USA), a personal genetics company, is collaborating with Pfizer, Inc. (New York, NY, USA), in which the companies will seek to enroll 10,000 people with inflammatory bowel disease (IBD) in a research project designed to explore the genetic factors associated with the onset, progression, severity,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.